New drug hope for patients with advanced cancers
NCT ID NCT04145622
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may continue treatment as long as it works and side effects are manageable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA CRPC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Aichi Cancer Center Hospital
RECRUITINGAichi, 464-8681, Japan
-
Cancer Institute Hospital of JFCR
RECRUITINGTokyo, 135-8550, Japan
-
Cedars-Sinai Medical Center- Samuel Oschin Comprehensive Cancer Institute
WITHDRAWNLos Angeles, California, 90048, United States
-
Columbia University Medical Center
WITHDRAWNNew York, New York, 10032, United States
-
Dana Farber Cancer Institute
ACTIVE_NOT_RECRUITINGBoston, Massachusetts, 02115, United States
-
Florida Cancer Specialists
WITHDRAWNOrlando, Florida, 32804, United States
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
-
Henry Ford Hospital
ACTIVE_NOT_RECRUITINGDetroit, Michigan, 48202, United States
-
Hokkaido University Hospital
RECRUITINGHokkaido, 060-8648, Japan
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
-
Kagawa University Hospital
RECRUITINGKagawa, 761-0793, Japan
-
Keio University Hospital
RECRUITINGTokyo, 160-8582, Japan
-
Kindai University Hospital
RECRUITINGŌsaka-sayama, 589-8511, Japan
-
Kobe City Medical Center General Hospital
RECRUITINGHyōgo, 650-0047, Japan
-
MDACC (MD Anderson Cancer Center)
ACTIVE_NOT_RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan-Kettering Cancer Center
ACTIVE_NOT_RECRUITINGNew York, New York, 10065, United States
-
National Cancer Center Hospital
RECRUITINGTokyo, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGChiba, 277-8577, Japan
-
SCRI Oncology Partners
ACTIVE_NOT_RECRUITINGNashville, Tennessee, 37203, United States
-
Saitama Cancer Center
RECRUITINGSaitama, 362-0806, Japan
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
-
Shizuoka Cancer Center
RECRUITINGShizuoka, 411-8777, Japan
-
Showa Medical University Hospital
RECRUITINGTokyo, 142-8666, Japan
-
Sidney Kimmel Cancer Center - Thomas Jefferson
WITHDRAWNPhiladelphia, Pennsylvania, 19107, United States
-
Tennessee Oncology
ACTIVE_NOT_RECRUITINGNashville, Tennessee, 37203, United States
-
The Ohio State University
WITHDRAWNColumbus, Ohio, 43210, United States
-
The University of Osaka Hospital
RECRUITINGOsaka, 565-0871, Japan
-
Washington University
ACTIVE_NOT_RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Can your own immune cells beat advanced cancer?
- Could ionized gas help fight breast cancer after surgery?